Sign in
CompletedNo phase

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

Key facts

Who runs it
Gruppo Italiano Malattie EMatologiche dell'Adulto
Where
Italy21 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
95 people enrolled
Started
5 May 2023
Ended
31 May 2024
Type of study
Observational
Treatments tested
  • Fostamatinib
Record updated
30 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients with chronic ITP who are refractory to other treatments and who received Fostamatinib according to standard clinical practice between October 1st, 2021 and April 1st, 2023
  • Age greater or equal to 18 years at the treatment start
  • Signed written informed consent document (if feasible) according to ICH/EU/GCP and national local laws

Who cannot take part

  • Contraindications or hypersensitivity to Fostamatinib, its active substance or any of its excipients
  • Patients participating in an interventional clinical trial at the time of enrollment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.

The group in the trial

  • Study group

    All patients being observed during the study duration.

    Treatment: Fostamatinib

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real World Evaluation Among Italian Centers of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With Immune Thrombocytopenia (ITP)
Record updated
30 April 2025